Loading patent…
AssigneeGovernment of the US, as represented by the Secretary, Department of Health and Human Services
InventorsDavid M. Neville, Jr., Jerry Todd Thompson, Huaizhong Hu, Jung-Hee Woo, Shenglin Ma, Jonathan Mark Hexham, Mary Ellen Digan
Estimating the term…
The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.
1-78. (canceled)
A nucleic acid encoding an anti-T cell immunotoxin fusion protein, comprising, from the amino terminus, a truncated diphtheria toxin moiety, a connector, and two single chain Fvs of the variable region of a UCHT1 antibody, wherein the two single chain Fvs comprise VL, L, VH, L, VL, L, VH, wherein L is a Gly-Ser linker, and wherein VL and VH are the variable light and heavy domains of the anti-CD3 antibody UCHT1.
-91. (canceled)
97-100. (canceled)
A nucleic acid encoding a diphtheria toxin-containing fusion protein, an anti-T cell immunotoxin fusion protein, wherein the nucleic acid can be expressed by a yeast cell.
The nucleic acid of 103, wherein one or more AT rich regions of the nucleic acid are modified to reduce the AT content.
113-119. (canceled)
Dependencies are inferred from the claim text.